Selpercatinib received accelerated approval from the FDA in 2020 for patients with metastatic RET fusion-positive NSCLC, and patients with RET-mutant aggressive or metastatic MTC (271, 272), making it the first FDA approval for RET fusion-positive NSCLC and MTC. This evidence concerns the gene RET and non-small cell lung carcinoma.